Research programme: HAAH cancer vaccine - Panacea

Drug Profile

Research programme: HAAH cancer vaccine - Panacea

Alternative Names: HAAH-1Lambda phage vaccine; HAAH-2Lambda phage vaccine; HAAH-3Lambda phage vaccine; nanoparticle HAAH vaccine

Latest Information Update: 15 Dec 2015

Price : $50

At a glance

  • Originator Panacea Pharmaceuticals
  • Class Bacteriophages; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Dec 2015 Panacea plans a phase I trial in Cancer in second quarter of 2016
  • 08 Dec 2015 Panacea intends to file an IND application with the FDA in USA for Cancer in first quarter of 2016
  • 10 Feb 2015 Panacea Pharmaceuticals and Accelovance enter a clinical development services agreement to develop and advance Panacea's oncology immunotherapy pipeline, including its HAAH cancer vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top